Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Inovio DNA Vaccine Candidate INO-4800 has Promising Results. Read Also: Sutro Biopharma Good News

April 15, 2021 0

Inovio Pharmaceuticals Promising Results for INO-4800 for COVID-19 Inovio Pharmaceuticals (INO) announces promising results of a …

Gilead Sciences: Another Accelerated Cancer Approval from the FDA

April 14, 2021 0

FDA Grants Accelerated Approval for Gilead Sciences Trodelvy® The United States Food and Drug Administration (FDA) …

The FDA Granted Breakthrough Therapy Designation to vTv Therapeutics for Type 1 Diabetes Product TTP399

April 13, 2021 0

vTv Therapeutics Receives Breakthrough Therapy Designation for TTP399 vTv Therapeutics (VTVT) - a clinical-stage biopharmaceutical company …

Re-Working Some Evaluated Biotechnology Firms

April 11, 2021 0

Prohost Portfolio PLUS #2 Re-Working Some Evaluated Biotechnology Firms Exelixis: 2020 and 2021 Wondering why Exelixis’ …

Gilead Sciences: FDA Fully Approves Trodelvy for Metastatic TNBC

April 8, 2021 0

Gilead Sciences is Granted FDA Approval for Trodelvy® Gilead Sciences (GILD), a company that has been …

Exelixis Latest News. See Also: TransMedics Group May Improve on Heart Transplants

April 7, 2021 0

Exelixis Latest News The latest news announced by Exelixis (EXEL) is the FDA acceptance of its …

Intellia Therapeutics Announces More Good News

April 5, 2021 0

Intellia Therapeutics NTLA-2001 for ATTR Granted Orphan Drug Designation by the EC Intellia Therapeutics (NTLA) announced …

Exelixis CABOMETYX: Now Approved in Europe for First-Line Treatment of Renal Cell Carcinoma

April 1, 2021 0

Exelixis Boxed in on Good News Exelixis (EXEL) is one of the firms boxed in by …

Illumina Acquisition of GRAIL: A Challenging Story That Boosted ILMN’s Stock Price

March 31, 2021 0

Illumina Acquisition of GRAIL On September 21, 2020, Illumina and GRAIL Inc. announced that they entered into …

A Biotech Firm We Love to Discover

March 30, 2021 0

Rubius Therapeutics Finding small development-stage biotech firms that contribute to biotechnology's limitless revolution of the biological …

Your Questions, Our Answers

March 28, 2021 2

Prohost Portfolio PLUS (formerly The Week in Review) Your Questions, Our Answers In the upcoming issues …

Intellia Therapeutics’ Important Current Presentations

March 25, 2021 0

Current Presentations from Intellia Therapeutics Intellia Therapeutics (NTLA) is presenting the first preclinical data set on …

Novartis Announced Positive Results of Phase 3 Study Using 177Lu-PSMA-617 in Advanced Prostate Cancer Patients

March 24, 2021 0

Novartis Positive Results for Radioligand Therapy, 177Lu-PSMA-617, for mCRPC Novartis (NVS) reported the first interpretable results …

A Flashback and Future Projections

March 24, 2021 0

Prohost Letter #445 A Flashback and Future Projections 1. A Follow-Up on Recently Posted News from …

Negative News from Ionis Pharmaceuticals Phase 3 Trial for Huntington’s Disease. Good News from the Regeneron Antibody Cocktail for COVID-19

March 23, 2021 0

Negative News from Ionis Pharmaceuticals Ionis Pharmaceuticals (IONS) announced that its partner, Roche (RHHBY),

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Inovio DNA Vaccine Candidate INO-4800 has Promising Results. Read Also: Sutro Biopharma Good News

Gilead Sciences: Another Accelerated Cancer Approval from the FDA

The FDA Granted Breakthrough Therapy Designation to vTv Therapeutics for Type 1 Diabetes Product TTP399

Re-Working Some Evaluated Biotechnology Firms

Gilead Sciences: FDA Fully Approves Trodelvy for Metastatic TNBC

Exelixis Latest News. See Also: TransMedics Group May Improve on Heart Transplants

Intellia Therapeutics Announces More Good News

Exelixis CABOMETYX: Now Approved in Europe for First-Line Treatment of Renal Cell Carcinoma

Illumina Acquisition of GRAIL: A Challenging Story That Boosted ILMN’s Stock Price

A Biotech Firm We Love to Discover

Your Questions, Our Answers

Intellia Therapeutics’ Important Current Presentations

Novartis Announced Positive Results of Phase 3 Study Using 177Lu-PSMA-617 in Advanced Prostate Cancer Patients

A Flashback and Future Projections

Negative News from Ionis Pharmaceuticals Phase 3 Trial for Huntington’s Disease. Good News from the Regeneron Antibody Cocktail for COVID-19

CureVac Has Very Interesting Future Plans

AstraZeneca to Supply Half a Million Additional Doses of the Potential COVID-19 Antibody Treatment AZD7442 to the U.S.

Immutep Ltd: Evaluating the Safety and Efficacy of Eftilagimod Alpha in Combination with Merck’s KEYTRUDA

Gilead Sciences and Merck: Long-Term Oral HIV Combination Treatment

Anixa Biosciences: Why This Firm Outperformed Today